

**(Under Corporate Insolvency Resolution Process)**

June 28,2019

**National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5th Floor, Plot No: C/1  
G - Block, Bandra - Kurla Complex  
Bandra (East)  
Mumbai – 400 051**

**BSE Limited  
Corporate Relationship Department  
1st floor, New Trading Ring  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai - 400 001**

**Sub: Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on March 31, 2019.**

Dear Sir/Madam

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we hereby submit the disclosure of Related Party transactions, on a consolidated basis for the half year ended March 31, 2019.

Kindly take the above on your records.

Thanking you

Yours faithfully



L Chandrasekar  
Executive VP – Finance & Secretary



**CONSOLIDATED DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED 31ST  
MARCH 2019**


**(i) List of parties having significant influence**

<b>Holding company</b>	The Company does not have any holding company
<b>Subsidiary company</b>	Orchid Europe Limited, UK Orchid Pharmaceuticals Inc., USA Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc. USA.) Orchid Pharma Inc / Karalex Pharma USA, (Subsidiary of Orchid Pharmaceuticals Inc, USA) Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa Bexel Pharmaceuticals Inc., USA Diakron Pharmaceuticals Inc., USA
<b>Key Management Personnel</b>	Mr. K. Raghavendra Rao, Managing Director Mr. L. Chandrasekar, Executive VP-Finance & Secretary
<b>Relatives of Key Management Personnel</b>	Mrs. R Vijayalakshmi, wife of Mr. K Raghavendra Rao  Ms R Divya and Ms R Sowmya, daughters of Mr. K. Raghavendra Rao
<b>Entities in which relatives of KMP exercise significant influence</b>	Orchid Healthcare Private Ltd.

**TRANSACTIONS WITH RELATED PARTIES FOR THE HALF YEAR ENDED 31.03.2019**

Amount (Rs.in Lakhs)

S.No.	Nature of transactions	From 1/10/2018-31/03/2019
1	Repayment of Unsecured advance	
	Orchid Healthcare Private Ltd.	
2	Sale of goods	
	Orchid Pharma Inc.	312.40
3	Availment of services/ reimbursement	
	Orchid Europe Limited	12.24
4	Remuneration and contribution to funds	
	K. Raghavendra Rao	15.32
	L. Chandrasekar	25.08





Balances at the end of the year		
Amount(Rs.in Lakhs)		
S.No.	Nature of transactions	As at March 31, 2019
1	Trade receivables	
	Orchid Pharma Inc.	2,127.93
2	Loans and advances (Current) *	
	Bexel Pharmaceuticals Inc., USA	3,585.47
	Diakron Pharmaceuticals Inc., USA	3.28
	Orchid Pharma Inc.	1,640.61
3	Short term borrowings	
	Orchid Healthcare Private Ltd.	3,216.77
4	Trade payables	
	Orchid Europe Limited	32.85
	Bexel Pharmaceuticals Inc., USA	266.52
	Orgenus Pharma Inc., USA	69.77
*	Provision has been made for the entire outstanding amount during the year.	

**For ORCHID PHARMA LTD.**

**Executive VP - Finance & Secretary**

